Trial Profile
A Randomized Double-Blinded Study of V-502 Administered to 16- to 26- Year-Old Women.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant octavalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections; Vulvovaginal cancer
- Focus Therapeutic Use
- Sponsors Merck & Co
- 09 Jan 2007 Status change
- 05 Nov 2006 New trial record.